Occurrence of mirtazapine-induced delirium in organic brain disorder

International Clinical Psychopharmacology

Volumn 15, Issue 4, 2000, Pages 239-243

  Bailer, Ursula ^a   Fischer, P ^a   Kufferle B ^a   Stastny, J ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dementia; Major depression; Mirtazapine induced delirium

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DIXYRAZINE; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LORAZEPAM; MIRTAZAPINE;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CASE REPORT; DELIRIUM; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0033919260     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015040-00009     Document Type: Article

References (32)

1. Ackenheil M, Athen D, Beckmann H (1978) Pathophysiology of delirious states. J Neural Transm 14:167-175.
2. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M (1997) Clinically defined vascular depression. Am J Psychiatry 154:562-565.
3. Bailer U, Praschak-Rieder N, Pezawas L, Kasper S (1998) Mirtazapin bei stationär behandelten depressiven patienten. Wien Klin Wochenschr 18:646-650.
4. Ballard C, Grace J, McKeith I, Holmes C (1998) Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 351:1032-1033.
5. Byrne EJ, Lennox G, Godwin-Austen RB, Jefferson D, Lowe J, Mayer RJ et al. (1991) The Notthingham group for the study of neurodegenerative disorders. Dementia associated with cortical Lewy bodies: proposed clinical diagnostic criteria. Dementia 2:283-284.
6. Claghorn JL (1996) Mirtazapine: a novel noradrenergic and specific serotonergic antidepressant. Today's Therapeut Trends 14:141-164.
7. Cusack B, Nelson A, Eichelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 114: 559-565.
8. De Boer T, Maura G, Raiter M, de Vos CJ, Wieringa J, Pinder RM (1988) Neurochemical and autonomic pharmacological profiles of the 6-AZA-analoguc of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 27:399-408.
9. π) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 10 (Suppl. 2):S107-S118.
10. De Boer T (1996) The pharmacological profile of mirtazapine. J Clin Psychiatry 57 (Suppl. 2): 19-25.
11. Delbressine LPC, Voss RME (1997) The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacot 17 (Suppl. 2):29S-34S.
12. Fischer P (1995) Serotonin syndrome in the elderly after antidepressive monotherapy. J Clin Psychopharmacol 15:440-442.
13. Fujikawa T, Yamawaki S, Touhouda Y (1993) Incidence of silent cerebral infarction in patients with major depression. Stroke 24:1631-1634.
14. Gerritsen AW (1997) Safety in overdose of mirtazapine: a case report. J Clin Psychiatry 58:271.
15. Halikas JA (1995) Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 10 (Suppl. 2): S125-S135.
16. Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Moeller HJ (1998) The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 248:96-103.
17. Hoes MJAJM, Zeijpveld JHB (1996a) First report of mirtazapine overdose. Int Clin Psychopharmacol 11:147.
18. Hoes MJAJM, Zeijpveld JHB (1996b) Mirtazapine as treatment for serotonin syndrome (letter). Pharmacopsychiatry 29:81.
19. Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekhdal P, et al. (1996) A double-blind, amitriptyline-controlled, multicentre stdy of Org 3770 in the treatment of elderly depressed patients. Acta Psychiat Scand 93:184-190.
20. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R (1997a) A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Safety 17:251-264.
21. Kasper S, Zivkov M, Roes KCB, Pols AG (1997b) Pharmacological treatment of severly depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 7:115-124.
22. Lennkh C, Fischer P, Küfferle B, Kasper S (1998) Occurrence of trazodone-induced delirium. Int Clin Psychopharmacol 13:225-228.
23. Livingston R, Zucker D, Isenberg K, Wetzel RD (1983) Tricyclic antidepressants and delirium. J Clin Psychiatry 44:173-176.
24. McEntee WJ, Crook TH (1990) Age-associated memory impairment. Neurology 40:526-530.
25. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK (1992a) Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 22:911-922.
26. McKeith IG, Fairbairn AF, Perry RH, Thompson P, Perry EK (1992b) Neuroleptic ssensitivity in patients with senile dementia of the Lewy body type. BMJ 305:673-678.
27. Montgomery SA (1995) Safety of mirtazapine: a review. Int Clin Psychopharmacol 10 (Suppl. 2):37-45.
28. Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J (1997) Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 30:263-265.
29. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303-308.
30. Peroutka SJ (1995) 5-HT receptors: past, present, future. Trends Neurosci 18:68-69.
31. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705-713.
32. Van der Maelen CP, Braselton JP (1990) Acute administration of the antidepressant trazodone increases noradrenergic locus coeruleus neuronal firing in rats. Arch Int Pharmacodyn Ther 308:13-20.